Cogent Biosciences Inc
Aperta
33.29 -1.92
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
33.24
Massimo
34.83
Entrata | 947K -96M |
|---|---|
EPS | -0.52 |
Dipendenti | 258 |
EBITDA | 537K -94M |
Utili prossimi | 2 nov 2026 |
|---|
Capitalizzazione di Mercato | -608M 6B |
|---|---|
Apertura precedente | 35.21 |
Chiusura precedente | 33.29 |
Cogent Biosciences Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Cogent Biosciences Inc Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.